View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 21, 2020

Moderna’s Covid-19 vaccine looks to gain first approval

By GlobalData Healthcare

On Tuesday 12 May, Moderna Therapeutics received Fast Track designation from the Food and Drug Administration (FDA) for its Covid-19 candidate vaccine, mRNA-1273. A few days before the approval, the FDA also approved Moderna to initiate a Phase II clinical trial study. Both the Fast Track designation and the start of the Phase II trial mean that mRNA-1273 may be the first to be approved and launched for the Covid-19 pandemic, as it is the only vaccine that has received FDA approval to initiate a Phase II trial, therefore placing it ahead of all other candidate Covid-19 vaccines in development. The candidate vaccine has been developed by Moderna in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and is the first vaccine in human clinical trials as a prophylactic intervention for Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Moderna plans to launch Phase III studies by this summer, assuming that the Phase II will be complete by then. The Phase II studies will include approximately 600 healthy volunteers, half of whom will be ages 18–55 years and half of whom will be over 55 years old. The volunteers will be randomly assigned to receive either a placebo or one of the two doses of mRNA-1273.

Other pharmaceutical companies have potential Covid-19 vaccines in development. One such company is AstraZeneca, which currently has its vaccine in a Phase I trial. This places it behind Moderna’s candidate vaccine, which will be in Phase II shortly. Therefore, GlobalData expects that Moderna’s vaccine will be the first to be FDA approved. However, it is notable that trials for Moderna’s vaccine are carried out in the US, whereas the trials for AstraZeneca’s vaccine are taking place in the UK.

In addition to vaccines, pharmaceutical companies also have several potential Covid-19 treatments in development, such as Gilead’s remdesivir, which recently received Emergency Use Authorization by the FDA. While there is an urgent need for a treatment to combat the Covid-19 pandemic, the development of a vaccine would be more effective as it could give immunity to the virus, therefore preventing the disease and the need for further treatment.

GlobalData believes that a Covid-19 vaccine would also be more cost-effective compared a treatment, as the vaccine will only need to be given once, whereas a patient would need regular medication if on treatment. Therefore, it would be highly beneficial to have a Covid-19 vaccine available globally.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena